Cell Permeability of Macrocycles Patents: Who Leads, Gaps 2026
Cell Permeability of Macrocycles: Patents Behind Oral Bioavailability Claims
Concentrated at the top. The top 5 assignees hold 55.7% of all 106 records in scope, and the top 10 hold 79.2% — a small group set the boundaries most new filers have to design around. Filings held near zero through 2017, then rose to a peak of 8 in 2023 before falling. The 2021-to-2024 span shows a drop from 6 to 1 filings, an 83% decline — but because publication typically lags filing by around 18 months, the 2025 and 2026 figures are still incomplete and should not be read as confirmation the field is slowing further.
- 1NASTECH PHARMA27
- 2CORNELL UNIVERSITY11
- 3CERCACOR LABORATORIES INC7
- 4THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD7
- 5UNITHER VIROLOGY7
See the full cell permeability of macrocycles analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on macrocycle permeability patents
What counts as a macrocycle permeability patent?
In this dataset, it is a filing that claims a macrocyclic or peptidic compound, formulation or design method where cell membrane permeability is the demonstrated inventive step, evidenced through metrics such as polar surface area, efflux ratio or passive diffusion assays. The search deliberately combines mechanism terms like intramolecular hydrogen bonding and conformational shielding with these measurement terms, so records where permeability is incidental rather than claimed are excluded. This keeps the corpus focused on molecules and methods purpose-built to cross membranes without active transport.
Who are the leading patent filers in macrocycle permeability?
The ranking covers 52 assignees across 106 records, and it is top-heavy: the leading assignee alone holds 27 records, well ahead of the fifth-place holder at 7 and tenth place at 4. The top 5 assignees combined account for 55.7% of all records in scope, and the top 10 account for 79.2%. Most other filers in the ranking appear with only a handful of records each, typical of a field seeded largely by academic and research-institute filings.
Is patent filing in this field growing or slowing down?
Filings peaked at 8 in 2023 after several thin years, then fell to 1 by 2024 — an 83% decline over the 2021-to-2024 span. That said, publication typically lags actual filing by around 18 months, so the 2025 and 2026 figures in any such dataset are still filling in and should not yet be read as a continued slowdown. The more reliable read is that 2023 marked a filing peak and 2024 shows a genuine pullback from it.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Cell Permeability of Macrocycles covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.